Peptic Ulcer Disease (PUD) remains a prevalent gastrointestinal disorder affecting millions worldwide. Its management has significantly evolved over the years, thanks to medical advancements that have enhanced diagnosis, treatment, and prevention strategies.
The advent of non-invasive tests, such as the urea breath test and stool antigen test, have revolutionized PUD diagnosis. These tests, which detect Helicobacter pylori, the bacterium implicated in most PUD cases, have improved diagnostic accuracy while minimizing patient discomfort.
Pharmacological management of PUD has seen significant advancements. Proton pump inhibitors (PPIs) remain the cornerstone of treatment, providing superior acid suppression and promoting ulcer healing. The introduction of quadruple therapy, including a PPI, bismuth, and two antibiotics, has improved eradication rates for H. pylori. Moreover, the development of cytoprotective agents like misoprostol provides additional options, especially for NSAID-induced ulcers.
Endoscopic techniques have transformed the management of complicated PUD. Endoscopic hemostasis, including injection, thermal, and mechanical therapies, has become the first-line treatment for bleeding ulcers, significantly reducing morbidity and mortality. Endoscopic submucosal dissection (ESD) has also emerged as a minimally invasive procedure for early gastric cancer associated with PUD.
Prevention strategies have focused on reducing risk factors, such as NSAID use and H. pylori infection. The development of COX-2 selective NSAIDs has minimized the risk of ulcers in patients requiring chronic NSAID therapy. Moreover, population-based H. pylori eradication programs have shown promise in reducing PUD incidence.
Peptic Ulcer Disease management has significantly evolved, with advancements in diagnostics, pharmacotherapy, endoscopic interventions, and preventive strategies. These developments have improved patient outcomes, but continuous research is necessary to further refine these strategies and address the challenges that remain.
1.
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
2.
Papillary thyroid cancer: New markers offer hope for tailored treatment
3.
What Comes After Cancer?
4.
FDA Expands Durvalumab Label to Operable Lung Cancer
5.
In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.
1.
Finding Support: Connecting with the Vitiligo Community
2.
Essential Updates in Hematology in Daily Practice
3.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
4.
Living Better With Advanced Cancer Through Supportive Care
5.
Understanding Epoetin and Its Role in Treating Chronic Kidney Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
2.
Updates on Standard V/S High Risk Myeloma Treatment
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation